K
Kenneth L. Scott
Researcher at Baylor College of Medicine
Publications - 73
Citations - 5614
Kenneth L. Scott is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 34, co-authored 71 publications receiving 4439 citations. Previous affiliations of Kenneth L. Scott include Harvard University.
Papers
More filters
Journal ArticleDOI
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Zhihu Ding,Chang-Jiun Wu,Gerald C. Chu,Yonghong Xiao,Dennis Ho,J. Zhang,Samuel R. Perry,Emma S. Labrot,Xiaoqiu Wu,Rosina T. Lis,Yujin Hoshida,David Hiller,Baoli Hu,Shan Jiang,Hongwu Zheng,Alexander H. Stegh,Kenneth L. Scott,Sabina Signoretti,Nabeel Bardeesy,Y. Alan Wang,David E. Hill,Todd R. Golub,Meir J. Stampfer,Wing Hung Wong,Massimo Loda,Lorelei A. Mucci,Lynda Chin,Ronald A. DePinho +27 more
TL;DR: This model-informed progression analysis, together with genetic, functional and translational studies, establishes SMAD4 as a key regulator of PCA progression in mice and humans.
Journal ArticleDOI
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang,Patrick Kwok Shing Ng,Melanie H. Kucherlapati,Fengju Chen,Yuexin Liu,Yiu Huen Tsang,Guillermo de Velasco,Guillermo de Velasco,Kang Jin Jeong,Rehan Akbani,Angela Hadjipanayis,Angeliki Pantazi,Christopher A. Bristow,Eunjung Lee,Harshad S. Mahadeshwar,Jiabin Tang,Jianhua Zhang,Lixing Yang,Sahil Seth,Semin Lee,Xiaojia Ren,Xingzhi Song,Huandong Sun,Jonathan G. Seidman,Lovelace J. Luquette,Ruibin Xi,Lynda Chin,Lynda Chin,Alexei Protopopov,Thomas F. Westbrook,Carl Simon Shelley,Toni K. Choueiri,Michael Ittmann,Carter Van Waes,John N. Weinstein,Han Liang,Elizabeth P. Henske,Andrew K. Godwin,Peter J. Park,Raju Kucherlapati,Kenneth L. Scott,Gordon B. Mills,David J. Kwiatkowski,Chad J. Creighton,Chad J. Creighton +44 more
TL;DR: A substantial fraction of cancers showed high mTOR pathway activity without an associated canonical genetic or genomic alteration, including cancers harboring IDH1 or VHL mutations, suggesting multiple mechanisms for pathway activation.
Journal ArticleDOI
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
Leng Han,Lixia Diao,Shuangxing Yu,Xiaoyan Xu,Xiaoyan Xu,Jie Li,Rui Zhang,Yang Yang,Yang Yang,Henrica M.J. Werner,Henrica M.J. Werner,A. Karina Eterovic,Yuan Yuan,Jun Li,Nikitha Nair,Rosalba Minelli,Yiu Huen Tsang,Lydia W.T. Cheung,Kang Jin Jeong,Jason Roszik,Zhenlin Ju,Scott E. Woodman,Yiling Lu,Kenneth L. Scott,Jin Billy Li,Gordon B. Mills,Han Liang +26 more
TL;DR: The effects of several cross-tumor nonsynonymous RNA editing events on cell viability are experimentally demonstrated and the evidence that RNA editing could selectively affect drug sensitivity is provided, highlighting RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.
Journal ArticleDOI
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer
Kenneth L. Scott,Omar Kabbarah,Mei-Chih Liang,Elena Ivanova,Valsamo Anagnostou,Joyce Wu,Sabin Dhakal,Min Wu,Shujuan Chen,Tamar Feinberg,Joseph Huang,Abdel Saci,Hans R. Widlund,David E. Fisher,Yonghong Xiao,David L. Rimm,Alexei Protopopov,Kwok-Kin Wong,Lynda Chin +18 more
TL;DR: In this article, the authors identify a Golgi protein, GOLPH3, as a candidate targeted for amplification in human cancer using integrative analysis of a genomic profile of the region.
Journal ArticleDOI
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma.
Carmit Levy,Mehdi Khaled,Dimitrios Iliopoulos,Maja M. Janas,Maja M. Janas,Steffen Schubert,Steffen Schubert,Sophie Pinner,Po-Hao Chen,Po-Hao Chen,Shuqiang Li,Shuqiang Li,Anne L. Fletcher,Satoru Yokoyama,Kenneth L. Scott,Levi A. Garraway,Levi A. Garraway,Jun S. Song,Scott R. Granter,Shannon J. Turley,David E. Fisher,Carl D. Novina,Carl D. Novina +22 more
TL;DR: The data implicate miR-211 as a suppressor of melanoma invasion whose expression is silenced or selected against via suppression of the entire melastatin locus during human melanoma progression.